Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.5652W HIGH $2.72
Volume
267.89 K
Value Traded
2.36 M
Short % Float
19.34%
-6.03%Week
-17.42%1 Month
-7.63%3 Month
+2.83%6 Month
-98.42%5 Year
-99.81%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
112.19 M
EPS (TTM)
-0.65
P/E Ratio
-
Ent. Value
76.03 M
Total Shares
103.40 M
Float Shares
103.01 M
Insiders
0.38%
Institutions
38.80%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
INO Catalyst Timeline
Dated clinical, regulatory and corporate events for Inovio Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Inovio Pharmaceuticals, Inc.
1458Total events
10Upcoming
391Tier-1 (high impact)
2010 to 2026Coverage
Upcoming catalysts 2
Event history 50
◆Poster PresentationPresentation
World Orphan Drug Congress Poster: Rare Disease Protein Replacement Therapeutics
Rare Diseasesource ↗
◆FDA ApprovalINO-3107FiledFDA Decision
Potential FDA approval in mid-2026
Recurrent Respiratory Papillomatosis (RRP)source ↗
◆PDUFA DateINO-3107FiledRegulatory Filing
PDUFA date for INO-3107 if priority review granted
recurrent respiratory papillomatosis (RRP)source ↗
◆Poster PresentationINO-3107FiledPresentation
B cell responses in Recurrent Respiratory Papillomatosis patients treated with DNA immunotherapy INO-3107
Recurrent Respiratory Papillomatosissource ↗
▲Topline ReadoutVGX-3100FiledClinical Data
Positive topline results from pivotal Phase 3 trial of VGX-3100 in cervical dysplasia
HPV-16/18-associated cervical dysplasia (HSIL)source ↗
▲Primary Endpoint MetVGX-3100FiledClinical Data
Primary endpoint met in Phase 3 trial of VGX-3100
HPV-16/18-associated cervical dysplasia (HSIL)source ↗
●Mid Cycle CommunicationINO-3107FiledRegulatory Filing
Mid-cycle review meeting completed with FDA
Recurrent Respiratory Papillomatosis (RRP)source ↗
●Oral PresentationINO-3107FiledPresentation
Data from Phase 1/2 trial of INO-3107 presented at COSM
Recurrent Respiratory Papillomatosis (RRP)source ↗
◆Poster PresentationPresentation
Bleeding phenotype correction in hemophilia A mice following in vivo Factor VIII gene transfer by electroporation in skeletal muscle cells
hemophilia Asource ↗
◆Oral PresentationPresentation
Next Gen Protein Replacement Therapeutics: DNA-Encoded Protein (DPROT) Technology Demonstrates in vivo Production of Functional FVIII in Mouse Model
Hemophilia Asource ↗
◆Poster PresentationPresentation
FVIII Expression Via Non-viral Vector DNA Medicine Platform Results in Efficacious Levels of FVIII Protein and Correction of the Bleeding Phenotype in Hemophilia A Mice
Hemophilia Asource ↗
▼Equity OfferingCorporate
Pricing of $17.5 million public offering of common stock and warrants
◆First Patient DosedINO-5412Trial
Dosing expected to begin in combination therapy trial
glioblastomasource ↗
◆FDA ApprovalINO-3107FiledFDA Decision
Potential approval and launch of INO-3107
Recurrent Respiratory Papillomatosis (RRP)source ↗
◆Oral PresentationPresentation
Novel DNA-Encoded Monoclonal Antibody Technology: Durable and Tolerable In Vivo Expression of mAbs Targeting COVID at World Vaccine Congress DC
COVIDsource ↗
◆Oral PresentationINO-3107FiledPresentation
DNA Immunotherapy INO-3107 Demonstrates Long-Term Surgical Intervention Reduction in HPV-6 & 11 RRP at Eurogin HPV Conference
HPV-6 & 11 RRPsource ↗
▲Partnership / LicenseINO-5412Corporate
Clinical trial collaboration and supply agreement with Akeso Inc. to evaluate INO-5412 in combination with cadonilimab in INSIGhT trial
Glioblastoma (GBM)source ↗
◆Quarterly UpdateCorporate
Q4 and full year 2025 financial results release and conference call
▲Partnership / LicenseINO-5412Corporate
Clinical trial collaboration and supply agreement with Akeso Inc. to evaluate INO-5412 in combination with cadonilimab
Glioblastoma (GBM)source ↗
▲Partnership / LicenseCorporate
Clinical trial collaboration and supply agreement between INOVIO and Akeso to evaluate INO-5412 plus cadonilimab in GBM
glioblastoma (GBM)source ↗
◆Oral PresentationPresentation
Presentation: Safety and Pharmacokinetics of SARS-CoV-2 DNA-Encoded Monoclonal Antibodies (DMAbs) in Healthy Adults: A Phase 1 Trial
COVID-19source ↗
▲Partnership / LicenseINO-5412Corporate
Clinical trial collaboration and supply agreement with Akeso Inc. for INO-5412 in combination with cadonilimab
Glioblastoma (GBM)source ↗
◆Oral PresentationPresentation
Fireside Chat at Oppenheimer 36th Annual Healthcare Life Sciences Conference
◆Poster PresentationINO-3107FiledPresentation
Poster Presentation: Treatment of RRP with DNA immunotherapy INO-3107 induces activation and enrichment of pro-inflammatory CD4+ T cell responses
Recurrent Respiratory Papillomatosis (RRP)source ↗
▲FDA Filing AcceptedINO-3107FiledRegulatory Filing
FDA accepted BLA for INO-3107 on standard review timeline
recurrent respiratory papillomatosissource ↗
▼FDA Feedback ReceivedINO-3107FiledFDA Meeting
FDA stated Inovio did not submit adequate info for accelerated approval; Inovio will request meeting to discuss
recurrent respiratory papillomatosissource ↗
●NDA SubmissionINO-3107FiledRegulatory Filing
Inovio filed BLA for INO-3107 under accelerated approval pathway
recurrent respiratory papillomatosissource ↗
▲AdCom CancelledINO-3107FiledAdvisory Committee
FDA indicated no advisory committee meeting planned
Recurrent Respiratory Papillomatosis (RRP)source ↗
▲BLA SubmissionINO-3107FiledRegulatory Filing
BLA for INO-3107 accepted for review by FDA
Recurrent Respiratory Papillomatosis (RRP)source ↗
◆Timing GuidanceINO-3107FiledPresentation
FDA acceptance of BLA submission expected by end of 2025
RRPsource ↗
▼FDA Feedback ReceivedINO-3107FiledFDA Meeting
FDA noted preliminary conclusion that adequate information for accelerated approval not provided; meeting to be scheduled
Recurrent Respiratory Papillomatosis (RRP)source ↗
◆Product LaunchINO-3107FiledPost-Market
Commercial launch ready by end of 2025
recurrent respiratory papillomatosis (RRP)source ↗
▼Equity OfferingCorporate
Pricing of $25 million public offering of 13,158,000 shares at $1.90 per share
●BLA SubmissionINO-3107FiledRegulatory Filing
Completed rolling submission of BLA for INO-3107
Recurrent Respiratory Papillomatosis (RRP)source ↗
▲PublicationINO-3107FiledPresentation
Long-term data from RRP-002 published in The Laryngoscope
Recurrent Respiratory Papillomatosis (RRP)source ↗
▲PublicationPresentation
Phase 1 DMAb proof-of-concept trial results published in Nature Medicine
COVID-19source ↗
●Preclinical PoCPreclinical
Preclinical DPROT data to be presented at World Federation of Hemophilia Global Forum
Hemophiliasource ↗
Past FDA Catalysts and PDUFA Decisions
How INO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-06-30 | INO-3107 | BLA Submission | BLA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C41 / 100
Pipeline Score
$65M
Pipeline Value
Overvalued
Valuation Signal
12
Drugs Scored
0.6x
rNPV / MCap
Top 36%
Micro Cap(rank 238 of 658)
Percentile Rank
Inovio Pharmaceuticals, Inc. carries a moderate pipeline score (41/100), with $1.7B risk-adjusted pipeline value, led by VGX-3100 in Cervical Intraepithelial Neoplasia (Phase 2), across $103B in total addressable markets, but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VGX-3100 Monoclonal antibodyCompletedNCT03185013 | Cervical Dysplasia | Phase 3 | COMPLETED | 404 | Apr 6, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every INO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| DNA-encoded monoclonal antibodies (DMAbs) | COVID-19 | Phase 1 | 2025-10-21 | 39/39 maintained biologically relevant levels of DMAbs through week 72 follow up; DMAbs successfully bound to the SARS-CoV-2 Spike protein and neutralized the SARS-CoV-2 pseudovirus target in all tested participants; no participant developed anti-drug antibodies (ADA) across ~1,000 blood samples; serum concentrations reaching a peak of 1.61 μg/mLRead More | Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature MedicineRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| YARNO WENDY LDirector | Grant/Award | 41,800 41,800 held | $0.00 | 05/20/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in INO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Boxer Capital Management, LLC | 0.2 % (-60 %) | 3.13 M | 2.84 M | 20.04% ( 474.87 K) |
INO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-12-18 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How INO ranks across every disease it competes in
Competitive Position is a premium feature
See how INO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialINO News
INOINOVIO to Participate in Upcoming Investor Conferences
INOVIO will participate in two upcoming investor conferences, including the Cantor Global Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference. The events will feature presentations and one-on-one meetings with investors. Replays of the presentations will be available for 90 days after the events.
Read more →INO▲ +16.9%on this news· ran to +56% by day 3
INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights
INOVIO has reported its financial results for Q2 2026, highlighting the ongoing FDA review of INO-3107 for Recurrent Respiratory Papillomatosis with a PDUFA date set for October 30, 2026. The company is preparing for a potential product launch and has reported positive Phase 3 trial results for VGX-3100. Despite a net loss of $6.0 million, INOVIO's operational strategies and reduced expenses indicate a focus on financial discipline.
Read more →INOINOVIO to Report Second Quarter Financial Results on August 12, 2026
INOVIO has announced that it will release its second quarter financial results on August 12, 2026. The company will host a live conference call and webcast at 4:30 p.m. ET to discuss these results and provide a business update. The event will include a Q&A session with analysts and will be archived for later access.
Read more →INO▼ -36.9%on this newsshared move
INOVIO Announces Pricing of $20.0 Million Public Offering
INOVIO Pharmaceuticals has announced a public offering of 21,052,632 shares of common stock, priced at $0.95 per share, aiming to raise approximately $20 million. The offering includes warrants for additional shares, and the underwriter has an option for more shares. The closing is anticipated around July 31, 2026, pending standard conditions.
Read more →INO▼ -36.9%on this newsshared move
INOVIO Announces Proposed Public Offering
INOVIO Pharmaceuticals announced its intention to conduct a public offering of common stock and warrants. The offering will be managed by Piper Sandler, who has been granted a 30-day option for additional shares. The company has filed a shelf registration statement with the SEC, but the offering is contingent on market conditions.
Read more →INOINOVIO to Participate in Upcoming Scientific and Investor Conferences
INOVIO Pharmaceuticals, focused on DNA medicines for HPV-related diseases and cancer, announced its participation in upcoming scientific and investor conferences. Notably, it will have a fireside chat at the Jefferies Global Healthcare Conference and a poster presentation at the World Orphan Drug Congress. The management team will also hold one-on-one meetings with investors, likely to strengthen their financial and collaborative engagements.
Read more →INOPositive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO’s Partner in China
INOVIO's partner ApolloBio announced positive topline results from a Phase 3 trial of VGX-3100, an investigational DNA immunotherapy for cervical dysplasia. The trial met its primary efficacy endpoint and showed a favorable safety profile. ApolloBio plans to use these results for a future regulatory submission in China, potentially offering a non-surgical treatment option for patients.
Read more →INOINOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights
INOVIO reported its financial results for Q1 2026, highlighting advancements in its lead product INO-3107 for recurrent respiratory papillomatosis (RRP). The FDA is reviewing the BLA for INO-3107, with a target PDUFA date set for October 30, 2026. INOVIO is also collaborating with Akeso Inc. to evaluate INO-5412 for glioblastoma treatment. The company remains focused on commercialization strategies and financial discipline.
Read more →INO▲ +6.6%on this newsshared move
INOVIO to Participate in Upcoming Scientific Conferences
INOVIO (NASDAQ:INO) has announced its participation in two prominent scientific conferences, the American Society of Gene and Cell Therapy Annual Meeting in Boston and the American Society of Clinical Oncology Annual Meeting in Chicago. At these events, the company will present research related to gene treatments for hemophilia A and DNA immunotherapy for Recurrent Respiratory Papillomatosis. Following the presentations, abstracts will be made available on INOVIO's website to share further details of the research.
Read more →INOINOVIO to Report First Quarter Financial Results on May 13, 2026
INOVIO Pharmaceuticals will release its first quarter 2026 financial results on May 13, 2026, after market close. A live conference call and webcast will follow at 4:30 p.m. ET, allowing analysts to engage in a Q&A session. The webcast will be archived for 90 days for later access.
Read more →INO▼ -35.1%on this newsshared move
INOVIO Announces Pricing of $17.5 Million Public Offering
INOVIO Pharmaceuticals has announced a public offering of 12.5 million shares, aiming to raise approximately $17.5 million. The offering includes Series A and Series B warrants, with a public offering price of $1.40 per share. The transaction is expected to close on April 6, 2026, pending customary conditions. Piper Sandler is managing the offering.
Read more →INOINOVIO to Participate in Upcoming Scientific Conference
INOVIO (NASDAQ:INO) has announced its participation in the World Federation of Hemophilia World Congress in Kuala Lumpur. The company will present on its DNA-Encoded Protein (DPROT) technology and its non-viral vector DNA medicine platform for hemophilia A. Abstracts will be available on INOVIO's website after the presentations.
Read more →INOINOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
INOVIO has reported its financial results for Q4 and full year 2025, highlighting the FDA's acceptance of its BLA for INO-3107 under review. The company is focused on advancing this treatment for recurrent respiratory papillomatosis while also preparing for commercialization. Positive clinical trial results support the efficacy of INO-3107, although the FDA has raised concerns about the adequacy of the submitted data for accelerated approval.
Read more →INOINOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
INOVIO Pharmaceuticals will announce its fourth quarter and full year 2025 financial results on March 12, 2026. The announcement will be followed by a live conference call and webcast at 4:30 p.m. ET, where the company will discuss the results and provide a business update. The event will include a Q&A session with analysts.
Read more →INOAkeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM) - March 4, 2026
Akeso and INOVIO have entered a clinical collaboration to evaluate the combination of cadonilimab and INO-5412 for glioblastoma treatment. This partnership will be part of the INSIGhT Phase II trial, aiming to discover new therapies for this aggressive cancer. Dosing is expected to begin in the latter half of 2026, leveraging the strengths of both companies' innovative treatments.
Read more →INOINOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
INOVIO and Akeso have announced a clinical collaboration to evaluate the combination of INO-5412 and cadonilimab for treating glioblastoma (GBM). The trial will be part of the INSIGhT platform, aimed at rapidly identifying effective therapies for this aggressive cancer type. This partnership builds on promising Phase 2 results indicating that the combination may enhance survival rates. Dosing for the trial is set to begin in the latter half of 2026.
Read more →About Inovio Pharmaceuticals, Inc.
Headquarters660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA, 19462
BIOPHARMAWATCH ELITE PLUS
Trade the next INO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime